100.00% -22.93

Landos Biopharma Inc (LABP)

Landos Biopharma Inc (LABP) 最新ニュース

Landos Biopharma Inc (LABP)

Landos Biopharma Inc (LABP) 最新ニュース

Orbimed Advisors LLC Reduces Stake in Passage Bio Inc - Yahoo Finance

OrbiMed Advisors sells shares of Passage Bio worth over $146,000 - Investing.com

Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications - AOL

NanoVation inks genetic medicines deal with Novo Nordisk - The Pharma Letter

Novo Nordisk and NanoVation Therapeutics enter collaboration on cardiometabolic and rare diseases - MedWatch

Novo Nordisk bets $600M biobucks on NanoVation's ability to take genetic medicines beyond the liver - Fierce Biotech

NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases - Business Wire

Nona Biosciences Enters Into Collaboration Agreement With Umoja Biopharma To Advance In Vivo CAR-T Cell Therapies - Technology Networks

Nabors Industries price target lowered to $115 from $140 at Morgan Stanley - TipRanks

Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates - Marketscreener.com

AbbVie inks immune disorder drug licensing deal with China's FutureGen - Reuters

AbbVie concludes acquisition of Landos Biopharma - Medical Dialogues

(LABP) Trading Report - Stock Traders Daily

Landos Biopharma (NASDAQ:LABP) Stock Price Up 0.6% - MarketBeat

Landos Biopharma (NASDAQ:LABP) Trading Up 0.6% - Defense World

AbbVie finalizes Landos Biopharma acquisition - Investing.com India

AbbVie finalizes Landos Biopharma acquisition By Investing.com - Investing.com

AbbVie finalizes Landos Biopharma acquisition By Investing.com - Investing.com UK

AbbVie Completes Acquisition of Landos Biopharma - PR Newswire

When the Price of (LABP) Talks, People Listen - Stock Traders Daily

LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC ... - Business Wire

LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC ... - Barron's

Landos Biopharma's Latest Deal Faces Tough Regulatory Gauntlet: HSR Act and FTC Scrutiny May Impose Delays ... - TipRanks

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates - Yahoo Movies UK

Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit OutlookAbbVie (NYSE ... - Benzinga

AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards? - Zacks Investment Research

Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie - Morningstar

AbbVie to Acquire Landos Biopharma and Novel Ulcerative Colitis Investigational Drug - Managed Healthcare Executive

This Biopharma Stock Outperformed MSTR and SMCI in March 2024TipRanks.com - TipRanks

ZUU Co. Ltd. executives purchase Pono Capital two shares worth $390 By Investing.com - Investing.com

Opinion: AbbVie-Landos Deal Signals Continued Momentum for Next-Gen I&I Drugs - BioSpace

AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio - Zacks Investment Research

AbbVie to acquire Landos Biopharma for $20.42 per share in cash plus CVRTipRanks.com - TipRanks

AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio - Yahoo Finance

Nasdaq Turns Higher; Akanda Shares Plunge - Benzinga

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Benzinga

Crude Oil Moves Higher; US New Home Sales Fall In February - Benzinga

US Stocks Down; Chicago Fed National Activity Index Rises In February - Benzinga

Landos Biopharma’s Definitive Merger with AbbVie Subsidiary - TipRanks

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases - GlobeNewswire Inc.

AbbVie to buy Landos Biopharma for $212M - USA Herald

Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely? - Simply Wall St

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results - GlobeNewswire Inc.

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results - Yahoo Finance

Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely? - Yahoo Finance

Landos’s NX-13 shows symptom relief in Phase Ib ulcerative colitis trial - Clinical Trials Arena

Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn's and Colitis - Yahoo Finance

Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results - Yahoo Finance

Ulcerative Colitis Market to Grow Positively by 2032, - GlobeNewswire

Scientists behind LANCL2 target launch with phase III-ready drug - BioWorld Online

Landos Biopharma Appoints Alka Batycky to Board - citybiz

Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D. - Yahoo Finance

Landos Biopharma Announces 1-for-10 Reverse Stock Split - Yahoo Finance

UPDATE -- Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results - GlobeNewswire

BRIEF—New biotech NImmune Biopharma buys assets from Landos | Pharmaceutical | The Pharmaletter - The Pharma Letter

Josep Bassaganya-Riera Launches NImmune Biopharma with Phase 3-Ready Clinical Candidate Omilancor for the Treatment of Ulcerative Colitis and Crohn’s Disease - Business Wire

Blacksburg biotech firm facing headwinds - Roanoke Times

Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual ... - GlobeNewswire

Landos Biopharma Provides Comprehensive Update on Clinical Development Plans - StockTitan

3 Top Biotech Penny Stocks Under $3 To Watch Right Now - Penny Stocks

Landos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical Officer - GlobeNewswire

Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial - GlobeNewswire

Landos Names Gregory Oakes President and Chief Executive Officer - GlobeNewswire

Landos Biopharma Appoints Roger Adsett to its Board of Directors - Yahoo Canada Finance

Swvl Hldgs Stock (NASDAQ:SWVL), Quotes and News Summary - Benzinga

Sonder Holdings Stock (NASDAQ:SOND), Quotes and News Summary - Benzinga

Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update - citybiz

Landos Biopharma gets dosing underway in early-stage LABP-104 lupus study - Seeking Alpha

Landos Biopharma’s Phase 2 Data of Omilancor in Ulcerative - GlobeNewswire

Vimeo Stock (NASDAQ:VMEO), Quotes and News Summary - Benzinga

Lianbio licenses Landos’ LANCL2- and NLRX1-targeted candidates in $218M deal for UC and CD - BioWorld Online

Perceptive Advisors Joins Biotech Investment Boom With $515M Fund - Business Insider

Bausch Health and Landos Biopharma See Activist Action - Barron's

LABP Stock Price and Chart — NASDAQ:LABP - TradingView

LABP IPO NewsAutoimmune biotech Landos Biopharma prices IPO at $16 midpoint - Renaissance Capital

Landos Biopharma Announces Pricing of Initial Public Offering - GlobeNewswire

LABP IPO NewsAutoimmune biotech Landos Biopharma sets terms for $100 million IPO - Renaissance Capital

LABPに似た銘柄